Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93875ArticlesСтатьиResearch ArticleStatiny i sakharnyy diabet: risk i pol'zaСтатины и сахарный диабет: риск и пользаDrapkinaO. MДрапкинаО. МSheptulinaA. FШептулинаА. ФГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ15052013155VOL 15, NO5 (2013)ТОМ 15, №5 (2013)606228122021Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93875

Результаты проведенных в течение двух последних десятилетий многоцентровых клинических исследований, включивших 170 тыс. пациентов, продемонстрировали эффективность статинов в отношении уменьшения частоты развития сердечно-сосудистых осложнений (ССО) [1]. Статины хорошо зарекомендовали себя в качестве препаратов для первичной и вторичной профилактики осложнений атеросклероза, в том числе инсульта [2]. Большинство терапевтических эффектов статинов обусловлено снижением уровня холестерина липопротеидов низкой плотности (ХС ЛПНП). Кроме того, в соответствии с результатами клинических исследований, статины уменьшают интенсивность воспалительного процесса в стенке сосудов, риск формирования тромбов и улучшают функцию эндотелия. Значение так называемых плейотропных эффектов статинов изучено недостаточно, и вопрос о степени влияния разных препаратов данной лекарственной группы на показатели заболеваемости и смертности от сердечно-сосудистых заболеваний (ССЗ) остается открытым [3]. Несмотря на тот факт, что эффективность статинов в отношении профилактики ССЗ подтверждена результатами многочисленных рандомизированных клинических исследований, перед назначением препарата необходимо оценить возможные риски, связанные с терапией статинами у каждого конкретного пациента.

Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta - analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.Uchechukwu K, Sampsona, Mac Rae F et al. Are statins diabetogenic? Curr Opin Cardiol 2011; 26 (4): 342–7.Jonas Rutishauser. Statins in clinical medicine. Swiss Med Wkly 2011.Cholesterol Treatment Trialists’ (CTT) Collaborators. Baigent C, Keech A, Kearney P.M et al. Efficacy and safety of cholesterol - lowering treatment: prospective meta - analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267–78.Mills E.J, Wu P, Chong G et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta - analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104 (2): 109–24.Yehuda Kamari, Rafael Bitzur, Hofit Cohen et al. Should All Diabetic Patients Be Treated With a Statin? Diabetes Care 2009; 32 (2).Turner R.C, Millns H, Neil H.A et al. Risk factors for coronary artery disease in non - insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8.Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160–78.Stamler J, Vaccaro O, Neaton J.D, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.Mc Carron P, Greenwood R, Elwood P et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001; 115: 12–20.American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31 (Suppl. 1): S12–54.Grundy S.M, Cleeman J.I, Merz C.N et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227–39.Justin W, Timbie Ph.D, Rodney A et al. Variation in the net benefit of aggressive cardiovascular risk factor control across the US diabetes population. Arch Intern Med 2010; 170 (12): 1037–44.Cannon C.P, Braunwald E, Mc Cabe C.H et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.Wu J, Kraja A.T, Oberman A et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005; 18 (7): 935–42.Zulman D.M, Vijan S, Omenn G.S, Hayward R.A. The relative merits of population - based and targeted prevention strategies. Milbank Quarterly Dec 2008; 86 (4): 557–80.Swapnil N, Rajpathak S, Dharam J et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta - Analysis. Diabetes Care 2009.Freeman D.J, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol - lowering with simvastatin in 5963 people with diabetes: a randomised placebo - controlled trial. Lancet 2003; 361: 2005–16.Results of the low - dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital Heart J 2000; 1: 810–20.Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid - Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.Shepherd J, Blauw G.J, Murphy M.B et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.Sever P.S, Dahlof B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149–58.Ridker P.M, Danielson E, Fonseca F.A et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.Sattar N, Preiss D, Murray H.M et al. Statins and risk of incident diabetes: a collaborative meta - analysis of randomised statin trials. Lancet 2010; 375 (9716): 735–42.David D, Waters et al. Predictors of New - Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. J Am Coll Cardiol 2011; 57: 1535–45.Sukhija R, Prayaga S, Marashdeh M et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 57: 495–9.Preiss D, Seshasai S.R, Welsh P et al. Risk of incident diabetes with intensive - dose compared with moderate - dose statin therapy. JAMA 2011;305 (24): 2556–64.